Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...

Wall Street’s major averages ended the week slightly lower on Friday, losing gains for the week amid renewed optimism about ...

For Reuters Pharma Europe 2025, pharmaphorum is providing coverage courtesy NAVLIN Daily, a pricing and market access insights report from EVERSANA (pharmaphorum's parent company). You can see the ...